Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Long Beach PET Imaging Center To Relocate To New Facility; Enhances Imaging Offering With Addition Of State-of-the-Art PET/CT Scanner
Long Beach PET Imaging Center, a leading diagnostic imaging center in the Long Beach, Calif.-area, announced it has relocated to a new, expanded facility at 2708 East Willow, Signal Hill, CA 90755, 562-427-0714, adjacent to Liberty Pacific Medical Imaging. The relocation is expected to be completed in August 2009. During the relocation process, all services including PET/CT and CT will remain in full operation without any interruption.

Inflammatory Molecules Promote Liver Scarring
Scarring of the liver, which can progress to cirrhosis and/or cancer of the liver, is caused by persistent liver damage, such as occurs in those with untreated hepatitis C or alcoholism. Although such scarring (fibrosis) develops in an inflammatory environment, the role of inflammatory molecules has not been well defined. However, a team of researchers at Columbia University, New York, and UCSD, La Jolla, has established that the proteins CCR1 and CCR5 and the soluble inflammatory molecules that bind to them promote the development of liver fibrosis in mice.
News of the day
Study Pinpoints Links Of Depression With Chronic Pain
It is well known that chronic pain and clinical depression go together, but a study in The Journal of Pain, published by the American Pain Society, shows that the connection between pain and depression is strongest in middle-age women and African Americans.
Oncology

Novel Cell Therapies To Treat Cancer

Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., has announced that it has entered into a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), with Steven A. Rosenberg, M.D., Ph.D., chief, Surgery Branch, serving as the NCI principal investigator, to research and develop novel cell therapy technologies as potential treatments for a variety of cancers. These adoptive immunotherapy technologies are designed to work by helping the immune system fight cancer. Standard cancer treatments still have not progressed much beyond surgery, radiation and chemotherapy, which are effective at killing tumor cells but also can harm or kill healthy tissues. Adoptive immunotherapies have the potential to spare healthy tissue because they are designed to directly find and destroy cancerous tumor cells using a patient"s own immune system T cells. Dr. Rosenberg has been a pioneer in the field of adoptive immunotherapy of cancer for decades. His group developed Tumor Infiltrating Lymphocytes (TILs), T cells obtained from a patient"s tumor, expanded and then re-administered to actively seek and destroy cancer cells. Remarkable responses to this therapy have been observed in patients with malignant melanoma, a type of skin cancer that ranks sixth among U.S. men and seventh in U.S. women for the most commonly diagnosed cancer, according to the NCI. In recent years, Dr. Rosenberg"s team pioneered a new technology in which T cells obtained from a patient"s blood are genetically engineered to express receptors that give them specific immunity against cancer cells and then re-administered. Researchers at Ortho Biotech Oncology Research & Development independently developed a different and proprietary adoptive immunotherapeutic approach that uses tumor antigens and other materials to stimulate T cells from a patient"s blood to become Cytotoxic T Lymphocytes (CTLs), which recognize and attack tumor cells. Early clinical results show that this technology holds promise in melanoma patients and also has the potential to work in other types of cancers. Under the CRADA, Dr. Rosenberg"s lab will conduct a clinical trial in melanoma patients using Ortho Biotech Oncology Research & Development"s proprietary technology. It is hoped that the technology will be effective in other types of cancer, as well. The other part of the CRADA will focus on a collaborative effort on a T-Cell Receptor (TCR) research program. "This public-private partnership represents an extraordinary opportunity to bring together complementary and substantial expertise and res from two groups with the common goal of advancing a highly promising new modality of therapy for patients with cancer," says Jay P. Siegel, M.D., chief biotechnology officer of Johnson & Johnson"s Pharmaceuticals and Medical Devices & Diagnostics businesses. "Dr. Rosenberg and NCI have extensive experience in the development of immunotherapies for melanoma and other cancers, as well as a strong track record in conducting early phase clinical studies. We look forward to collaborating with NCI to optimize technologies and to begin testing of our immunotherapy technology in melanoma patients by the end of 2009, with the possibility of additional studies for other types of cancer and other technologies in years to come," adds William N. Hait, M.D., Ph.D., senior vice president and worldwide head of oncology research and development, who with Dr. Siegel will direct the Ortho Biotech Oncology Research & Development team under the collaboration. Melanoma: Skin cancer is the most common form of cancer in the United States, and Melanoma, its most deadly form, accounts for 4 percent of all diagnosed skin cancers, according to NCI. Melanoma, which usually begins in cutaneous melanocytes - the cells that produce the pigment melanin - is more likely to spread to other body parts, known as metastatic melanoma. In 2008 in the United States, an estimated 68,000 people were diagnosed with melanoma and 8,420 people died. The percentage of people in the United States who develop melanoma has more than doubled in the last 30 years. When detected early, melanoma can be successfully treated with surgery; however, more advanced disease has limited treatment options, with a poor prognosis. Treatment of patients with melanoma in the United States costs about $1.5 billion annually, NCI reports. William Foster, J&JPRD Porter Novelli


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009